• Primary Outcomes: Assess the efficacy and safety of DAVANAT administered with 5-FU, LV, and Avastin® in the first-line treatment of unresectable, locally advanced, and/or metastatic CRC.
  

This is a Phase II, multi-center study of DAVANAT which has been shown to increase the anti-tumor activity of 5-FU in mice. 5-FU is a chemotherapy drug commonly used to treat tumors. A Phase I study of 40 patients showed that DAVANAT in different doses plus 5-FU was well tolerated in patients with different types of solid tumors who failed standard, approved treatments.

Inclusion Criteria:

• 18 years or older.
• Histologically confirmed, unresectable, locally advanced or metastatic colorectal adenocarcinoma (stage III and IV), not amenable to curative surgery or radiotherapy.
• Intolerant of oxaliplatin and/or irinotecan, as demonstrated by unacceptable toxicity after a trial of these agents as first-line therapy, or in the opinion of the Investigator, be judged at high risk for unacceptable toxicity to oxaliplatin and/or irinotecan,
• Presence of at least 1 measurable lesion,
• Have a life expectancy of at least 4 months.
• Women of childbearing potential, have a negative serum pregnancy test at screening and Day 1 treatment and agree to practice abstinence or use an effective method of contraception.

Exclusion Criteria:

• Central nervous system metastasis.
• Bony metastasis as the sole metastasis.
• Received any prior first-line chemotherapy for colorectal cancer.
• Previously exposed to DAVANAT® or Avastin®.
• Known or clinically suspected infection with HIV.
• Participated within 30 days or will participate concurrently in another investigational drug or vaccine study.
• History of drug or alcohol dependence in the past 3 years.
• Other serious, non-malignant, significant, acute or chronic medical or psychiatric illness that in the judgment of the Investigator could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study.